EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- ViroPharma Incorporated (VPHM) reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012. The increase was primarily driven by growth in U.S. Cinryze sales. Cinryze U.S. sales of $102 million during the quarter reflect true patient demand as channel inventory levels remain unchanged from the prior quarter.
Help employers find you! Check out all the jobs and post your resume.
